Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib + Docetaxel in Advanced NSCLC
NCT02922777Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2016
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemcentinib in non-small cell lung cancer (NSCLC), sponsored by UT Southwestern Medical Center. Primary endpoint: Maximum Tolerated Dose at 42 days. Started Nov 2016; status: completed.
02
Drugs
bemcentinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02922777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922777.